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PolysomnographyAbstract Objectives: The purpose of this study was to assess the prevalence of SRBDs in acutely
ill patients admitted to respiratory ICU.
Patients and methods: The study enrolled 72 patients admitted to respiratory ICU. All patients
were subjected to full clinical examination, Epworth Sleepiness score, arterial blood gases analysis
and clinical apnea score calculation. According to this latter, patients were divided into group I:
without clinically suspected SRBDs and group II: with clinically suspected SRBDs. Patients in
group II were subjected to polysomnography.
Results: Group I included 21 patients while group II included 51 patients. The BMI, neck circum-
ference and waist/hip ratio were significantly higher in group II. Hypertension was the commonest
comorbidity in group II. Type II respiratory failure was the commonest cause of ICU admission in
both groups of patients. The mortality rate was higher within the 28 days that followed ICU admis-
sion in group I compared to group II. This latter group had a higher mortality rate later on. All
patients subjected to polysomnography suffered fromOSAHS, 82% of them showed associated sleep
hypoventilation (SHV) with significantly elevated bicarbonate level. More than half the patients with
SHV fulfilled the criteria of obesity hypoventilation syndrome. The AHI showed a significant direct
correlation with neck circumference, systolic blood pressure, snoring index and T85%; and a signif-
icant inverse correlation with PaO2, minimal saturation as well as average saturation.
Conclusion: In ICU patients, SRBDs are common coexistent findings and every physician should
systematically search for them. Type II respiratory failure is the main cause of ICU admission in
patients with SRBDs. Quality of sleep in ICU is very disturbed.Most ICU patients with SRBDs have
concomitant SHVS mostly due to OHS. Important comorbidities coexist in patients with SRBDs;
both influence each other and should be identified and managed properly for the wellbeing of the
patient. BiPAP therapy is the cardinal mode of ventilation used in patients with respiratory failure
and SRBDs.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
90 M.I. Mahmoud et al.Introduction
Sleep related breathing disorders (SRBDs) are common in the
general population. They can cause or exacerbate preexisting
medical and psychiatric conditions and lead to significant mor-
bidity such as depression, anxiety, impaired daytime function-
ing, poor occupational performance, motor vehicle accidents,
cardiovascular and endocrine disorders [1].
Even though there is a large body of literature on sleep
apnea in the outpatient setting, there is a paucity of data about
the inpatient setting. An unmanaged SRBD in the hospital
may delay recovery from illnesses and prolong hospital stay.
Nevertheless, there are no studies on large inpatient popula-
tions that have looked into the potential effects of SRBD
and acute illness on each other [2]. Critically ill patients, espe-
cially in an intensive care unit (ICU) have decreased quality
and quantity of sleep attributable to environmental,
psychological, and physiologic factors such as noise, pain,
and awakenings from nursing care. The presence of SRBD
would further disturb their sleep [3]. As most patients with
SRBD have not been diagnosed; it is not uncommon for a
patient to have this disease first recognized while in the inten-
sive care unit. Sleep apnea by itself is not generally a cause of
respiratory failure, and most patients except those with the
obesity hypoventilation syndrome will have normal arterial
blood gases, at least while awake. However, this disease does
decrease respiratory drive, and may worsen respiratory failure
from another cause [4].
The purpose of this study was to assess the prevalence of
SRBDs in acutely ill patients admitted to respiratory ICU
and to identify patients’ characteristics that aid in predicting
SRBDs in such population.
Patients and methods
The study enrolled 72 patients admitted to respiratory ICU in
the Alexandria main university hospital during the period from
July 2012 to December 2012. The local ethics committee
approved the study and all participants signed an informed
consent. Upon admission all patients were subjected to full his-
tory taking including symptoms related to SRBDs, Epworth
Sleepiness score [5], complete clinical examination, routine lab-
oratory work up, arterial blood gases analysis, plain chest
X-ray, and electrocardiogram. Anthropometric measures were
taken including: body mass index (BMI); neck [6], waist and
hip [7] circumferences; and waist–hip ratio was calculated.
When the patient could not move, weight and height measure-
ments were obtained using specific equations [8]. Finally, the
APACHE II score was calculated from 13 routine physiologi-
cal measurements [9].
The clinical apnea score [10] was calculated for all patients.
It is a score of 5 items including: loud, habitual snoring;
interrupted breathing as reported to the patient by the
spouse or family members; excessive daytime sleepiness as
evidenced by Epworth Sleepiness score; obesity, defined as a
BMI > 25 kg/m2; essential hypertension identified by the use
of antihypertensive medications or blood pressureP 140/90
in two or more separate occasions. Patients were given a score
of one for each positive item with a maximum score of five.
Then the patients were divided into 2 groups according to their
score:Group I: patients without clinically suspected SRBDs based
on a score <2.
Group II: patients with clinically suspected SRBDs based
on a score P2.
All patients in group II were planned for full polysomno-
graphic study. The latter was carried out using somnoscreen
plus RC combi 39, which included the following channels: flow
(cannula and/or thermistor), snore (cannula and/or micro-
phone), thoracic movement, abdominal movement, oxygen
saturation, plethysmogram, pulse rate, electrocardiogram,
periodic leg movement, electrooculogram, electroencephalo-
gram and CPAP/BiPAP pressure. According to the presence
of sleep hypoventilation (SHV) as defined by the evidence of
sagging of oxygen saturation curve in the polysomnogram,
group II patients were further subdivided into two subgroups:
Group IIa: patients without SHV.
Group IIb: patients with SHV.
The polysomnographic analysis was done automatically
but was imperatively coupled with manual scoring. The analy-
sis included:
 Sleep stage analysis. It identified different sleep stages such
as Non-REM (rapid eye movement) and REM sleep. It cal-
culated total sleep time and efficiency. It recorded microar-
ousal index and percent of respiratory related ones.
 Respiratory event analysis. It determined apnea hypopnea
index (AHI) and respiratory disturbance index (RDI). It
identified different types of apneas: obstructive, central or
mixed and calculated their absolute values and indices. It
estimated respiratory effort related arousal (RERA) index
and absolute value. It measured the snoring index.
 Oxygen saturation analysis. It determined baseline, average
and minimal oxygen saturation. It estimated oxygen desat-
uration index (ODI) as well as T90% (time of sleep with
oxygen saturation below 90%) and T85%.
 Heart rate analysis. It measured maximal, minimal and
average heart rate. It calculated acceleration, deceleration
and arrhythmia indices as well as determined the type of
arrhythmia.
 Diagnosis. It recognized the presence or absence of obstruc-
tive sleep apnea hypopnea syndrome (OSAHS) and its
severity, central sleep apnea syndrome (CSAS) as well as
sleep hypoventilation syndrome (SHVS).
All the patients were followed up for six months. The lines
of treatment in the ICU including the mode of ventilation, the
length of ICU stay and the mortality rate as well as recurrence
of ICU admission were recorded.
Statistical analysis
Data were analyzed by SPSS 17.0 for Windows (SPSS Inc.,
Chicago, Illinois, USA). All hypotheses were constructed
two-tailed and p 6 0.05 was considered significant. Continuous
variables were expressed as mean ± standard deviation, ordi-
nal variables as median and minimum–maximum, and fre-
quent variables as rates. Student t-test was used to compare
data from two samples that were both normally distributed,
and had the additional requirement that the standard devia-
tions (SDs) from the two samples were approximately equal.
A nonparametric alternative to the unpaired t-test was given
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Mann–Whitney test. This test was nonparametric because it
was based on the ranks of the individual observations rather
than on their actual values, which would be used in the t test.
Chi-square test, a test of association, involved calculating the
differences between the observed and expected frequencies. If
the differences are large, then this suggests that there is an
association between one variable and the other. Fisher’s exact
test was a statistical significance test used in the analysis of
contingency tables. Although in practice it was employed when
sample sizes were small, it was valid for all sample sizes. It was
one of a class of exact tests, so called because the significance
of the deviation from a null hypothesis (e.g.: p-value) could be
calculated exactly, rather than relying on an approximation
that became exact in the limit as the sample size grows to infin-
ity, as with many statistical tests. 
72 Paents 
All studied paents 
Group I 
 No SRBDs Suspected 
 21pts (29%) 
Group II 
SRBDs Suspected 
51pts (71%) 
12pts (23%) 
PSG not performed 
39pts (77%) 
PSG Performed 
 
Group IIa 
SRBDs  
7pts (18%) 
Group IIb 
SRBDs + SHVS 
32pts (82%) 
Figure 1 Diagram showing the distribution of all the studied
patients.
Table 1 Patients’ characteristics, laboratory investigations and arte
Characteristics Group I (n= 21)
Anthropometric measures
Age (years) 50.8 ± 14.8
Body mass index (kg/m2) 24.9 ± 4.4
Waist/hip ratio 0.9 ± 0.1
Neck circumference (cm) 36.0 ± 2.0
Laboratory investigations
Hematocrit (%) 39.8 ± 9.6
WBC count 15.1 ± 8.6
Fasting blood sugar (mg/dl) 111.4 ± 38.3
Post-prandial blood sugar (mg/dl) 149.5 ± 37.1
Total Protein (gm/dl) 5.5 ± 1.1
SGPT (IU/dl) 168.7 ± 467.8
Cholesterol (mg/dl) 143.5 ± 54.5
Triglyceride (mg/dl) 81.9 ± 16.3
Serum uric acid (mg/dl) 6.4 ± 4.3
Arterial blood gases
PaO2 (mmHg) 64.6 ± 29.7
PaCO2 (mmHg) 59.1 ± 24.4
pH 7.35 ± 0.13
Bicarbonate (mmol/L) 29.0 ± 7.8
t: t-test; Z: Mann Whitney test.
* Significant at p 6 0.05.Results
The patients’ distribution is shown in Fig. 1. Group I included
21 patients while group II, those with high clinical probability
of SRBDs included 51 patients (Fig. 1). Table 1 shows the
characteristics of both groups of patients. The BMI, waist
hip and neck circumference as well as the waist/hip ratio were
significantly higher in group II than in group I (Fig. 2).
The comorbidities and clinical apnea scores of both groups
of patients are shown in Table 2. Hypertension was by far the
commonest comorbidity in group II followed by cardiac dis-
eases; while in group I chest diseases were by far the common-
est comorbidity. As expected, clinical apnea score was
significantly higher in group II than group I.
The cause of ICU admission, lines of management and fol-
low up are shown in Table 3. Type II respiratory failure was by
a long way the commonest cause of ICU admission in both
groups of patients. The mortality was higher within the
28 days that followed ICU admission in group I compared
to group II. This latter had a higher mortality later on.
All patients in group II were scheduled for polysomnogra-
phy. However, this latter could not be performed in 12 patients
due to death in 6 patients, transfer to another care unit in 3 of
them and refusal of the test in another 3 patients. The rest of
the group, 39 patients was subjected to polysomnography
which proved all of them to have SRBDs. The polysomno-
graphic data of those patients revealed a total sleep time of
4.5 ± 1.4 h (range: 1.03–12.43); a sleep efficiency of 67.0
± 26.0% (range: 16–96); light sleep stage time of 53.9
± 26.7% of total sleep time (range: 29–93); deep sleep stage
time of 23.5 ± 22.5% of total sleep time (range: 0–75) and
REM sleep stage of 12.3 ± 12.3% of total sleep time (range:
0–51). The microarousal index was 3.6 ± 6.6 per hour (range:
0–33) and a percent of respiratory related microarousal ofrial blood gases.
Group II (n= 51) Significance
59.1 ± 12.5 t= 2.408 p= 0.019*
40.37 ± 9.76 t= 8.666 p< 0.0001*
1.1 ± 0.1 Z= 5.002 p< 0.0001*
42.9 ± 3.9 t= 9.767 p< 0.0001*
42.1 ± 11.2 t= 0.836 p= 0.406
11.4 ± 6.3 t= 2.038 p= 0.045*
130.2 ± 48.9 t= 1.443 p= 0.155
202.1 ± 90.2 t= 3.2 p= 0.002*
6.2 ± 1.1 t= 2.402 p= 0.019*
46.3 ± 39.2 Z= 2.649 p= 0.008*
194.7 ± 64.2 t= 2.442 p= 0.018*
102.0 ± 32.7 t= 2.905 p= 0.007*
8.7 ± 2.7 t= 2.363 p= 0.022*
57.5 ± 17.0 t= 1.278 p= 0.206
62.1 ± 20.7 t= 0.536 p= 0.594
7.31 ± 0.08 t= 0.781 p= 0.175
30.7 ± 8.4 t= 0.79 p= 0.432
Figure 2 Body mass index and neck circumference in group I and group II.
Table 2 Patients’ comorbidities and clinical apnea score.
Group I (n= 21) Group II (n= 51) Significance
Co-morbidities
Diabetes mellitus 5 (23.8%) 21 (41.2%) X2 = 1.945 p= 0.163
Hypertension 2 (9.5%) 38 (74.5%) X2 = 25.442 p< 0.0001*
Chest diseases 20 (95.2%) 27 (52.9%) X2 = 11.74 p< 0.0001*
COPD 10 (47.6%) 22 (43.1%)
Pneumonia 1 (4.8%) 1 (2.0%)
Bronchiectasis 3 (14.3%) 0 (0.0%)
Pleural disease 1 (4.8%) 0 (0.0%)
Interstitial lung diseases 3 (14.3%) 2 (3.9%)
Pulmonary embolism 2 (9.5%) 2 (3.9%)
Cardiac diseases 11 (52.4%) 30 (58.8%) X2 = 0.25 p= 0.616
Arrhythmia 9 (42.8%) 9 (17.6%)
Ischemic heart diseases 1 (4.8%) 4 (7.8%)
Decompensated heart failure 1 (4.8%) 4 (7.8%)
Corpulmonale 8 (38.1%) 17 (33.3%)
Hypothyroidism 0 (0.0%) 6 (11.8%) FEp= 0.171
Renal impairment 1 (4.8%) 14 (27.5%) FEp= 0.052
Malignancy 4 (19.0%) 1 (2.0%) FEp= 0.023*
Cerebrovascular stroke 1 (4.8%) 4 (7.8%) FEp= 1.0
Previous usage of CPAP or oxygen 0 (0.0%) 8 (15.7%) FEp= 0.095
CPAP 0 (0.0%) 4 (7.8%)
Oxygen 0 (0.0%) 1 (2.0%)
Oxygen and CPAP 0 (0.0%) 3 (5.9%)
Clinical apnea score 0.3 ± 0.5 3.4 ± 1.1 Z= 6.766 p< 0.0001*
FEp: Fisher’s exact test; X2: Chi-square test; Z: Mann–Whitney test.
* Significant at p 6 0.05.
92 M.I. Mahmoud et al.31.9 ± 29.4 (range: 0–100). The respiratory and oxygen
saturation data as well as the heart rate analysis as scored from
the sleep study are shown in Table 4, Figs. 3 and 4. The snor-
ing analysis showed a snoring index of 153.9 ± 149.4 (range:
5–551.3) and a snore percent of total sleep time of 11.5
± 12.9% (range: 0.0–47.0). The arrhythmia index was 104.6
± 174.4. As regards the types of arrhythmia detected during
polysomnogram, premature atrial contractions were thecommonest encountered in 21 patients (53.8%) followed by
bradytachyarrhythmia encountered in 18 patients (46.2%).
Premature ventricular contractions were met in 16 patients
(41%), sinus tachycardia in 14 patients (35.9%) and atrial
fibrillation in 4 patients (10.3%).
The polysomnographic studies revealed that all 39 patients
suffered from OSAHS. The latter was mild in 10.2% of
patients (n= 4), moderate in 25.6% (n= 10) and severe in
Table 3 Patients’ diagnosis, management and follow up.
Group I (n= 21) Group II (n= 51) Significance
Diagnosis on admission
Type II respiratory failure 15 (71.4%) 41 (80.4%) MCp= 0.022*
Type I respiratory failure 5 (23.8%) 2 (3.9%)
Pulmonary edema 0 (0.0%) 3 (5.9%)
Shock 0 (0.0%) 4 (7.8%)
Cerebrovascular stroke 1 (4.8%) 1 (2.0%)
Total APACHE II score 20.7 ± 7.9 19.1 ± 6.8 t= 0.858 Z= 0.394
Predicted death rate 39.8 ± 24.6 34.3 ± 20.3 Z= 0.54 p= 0.589
Assisted ventilation and oxygen therapy
Oxygen therapy 6 (28.6%) 4 (7.8%) MCp< 0.0001*
CPAP 0 (0.0%) 10 (19.7%)
BIPAP 4 (19.0%) 28 (54.9%)
Invasive mechanical ventilation 11 (52.4%) 9 (17.6%)
Length of ICU stay (days) 8.8 ± 6.1 9.5 ± 11.5 Z= 0.597 p= 0.551
Number of ICU admission over 6 months
Once 14 (66.7%) 46 (90.2%) FEp= 0.032*
Twice 7 (33.3%) 5 (9.8%)
Mortality
Deceased within 28 days 9 (42.8%) 11 (21.6%) MCp= 0.091
Deceased from 28 days – 6 months 0 (0.0%) 5 (9.8%)
Alive after 6 months 12 (57.1%) 35 (68.6%)
FEp: Fisher’s exact test; t: t-test; MCp: Monte Carlo test; Z: Mann Whitney test.
* Significant at p 6 0.05.
Table 4 Respiratory, oxygen saturation and heart rate data at polysomnography.
Studied patients with SRBDs (n= 39)
Min–Max Mean ± SD Min–Max Mean ± SD
AHI 6.5–135.2 50.5 ± 37.3 ODI 3% 1.0–125.7 42.9 ± 35.5
RDI 6.5–135.7 51.0 ± 37.2 ODI 4% 1.0–122.0 39.67 ± 35.35
Hypopnea index 0.7–120.5 28.4 ± 23.7 Average minimal saturation 48–93 77.9 ± 10.5
Obstructive apnea index 0.0–90.5 20.4 ± 23.2 Minimal saturation 37–92 64.8 ± 13.1
Mixed apneas index 0.0–14.6 0.9 ± 2.8 Baseline saturation 63–96 85.5 ± 7.4
Central apnea index 0.0–14.5 0.8 ± 2.6 Average saturation 54.0–96.0 81.41 ± 9.79
RERA 0.0–2.9 0.4 ± 0.7 T90% 0.0–100.0 66.0 ± 35.6
Average circulatory delay 13.5–25.7 19.6 ± 2.9 T85% 0.0–100.0 52.47 ± 37.58
Acceleration index 0.0–110.0 24.1 ± 29.9 Deceleration index 0.0–124.3 9.1 ± 23.3
Arrhythmia index 0.0–732.0 104.6 ± 174.4 Average heart rate 58–150 90.8 ± 20.6
Minimal heart rate 49–110 73.8 ± 18.1 Maximum heart rate 84–207 125.0 ± 29.4
AHI: apnea/hypopnea index; RDI: respiratory disturbance index; RERA: respiratory effort related arousal index; ODI 3%: oxygen desatu-
ration more than 3% index; ODI 4%: oxygen desaturation more than 4% index; T90%: sleep time with oxygen saturation < 90%; T85%: sleep
time with oxygen saturation < 85%.
Sleep related breathing disorders 9364.1% (n= 25) of patients. Concomitant significant CSAS
was encountered in 2 patients. The OSAHS patients were
divided to two groups according to the associated SHVS:
group IIa: those without SHVS which constituted 18%
(n= 7) of patients; and group IIb: those with SHVS which
constituted 82% (n= 32) of patients.
As regards association between COPD and SRBDs, we
found fifteen patients in group II (representing 20.8% of all
patients) to have AHI > 5/h and COPD with or without
SHVS i.e. overlap syndrome. Since we had thirty patients in
this study suffering from COPD, it means that 50% of them
proved to have overlap syndrome.The comparison between the characteristics of group IIa
and group IIb is shown in Table 5. Among all the arterial
blood gases analysis, only the serum bicarbonate level showed
a statistically significant difference being higher in group IIb
(Fig. 5). All anthropometric measures did not show any signif-
icant difference between the two groups. The pattern of obesity
showed a central obesity in all patients (100%) in group IIa
and in 29 patients (90.6%) in group IIb. There was no
statistically significant difference between the two groups
(p= 1.000).
Seventeen patients (53.1%) of group IIb, who represented
43.6% of patients with SRBDs and 23.6% of all the patients,
Figure 3 Oximetric values in the polysomnogram of the studied patients.
Figure 4 Apnea hypopnea and respiratory disturbance indices in the studied patients.
Table 5 Characteristics of group IIa and group IIb.
Group IIa (n= 7) Group IIb (n= 32) Significance
Age (years) 59.29 ± 12.22 57.31 ± 12.48 tp= 0.709
Body mass index (kg/m2) 39.11 ± 5.19 41.70 ± 10.29 tp= 0.524
Waist circumference (cm) 126.14 ± 8.99 127.47 ± 22.67 tp= 0.803
Hip circumference (cm) 119.14 ± 6.62 118.88 ± 18.45 tp= 0.949
Waist/hip ratio 1.06 ± 0.03 1.07 ± 0.07 tp= 0.539
Neck circumference (cm) 41.43 ± 3.31 44.0 ± 3.75 tp= 0.103
Hematocrit (%) 37.71 ± 10.20 45.09 ± 10.64 tp= 0.103
PaO2 (mmHg) 76.86 ± 32.86 53.03 ± 15.76
tp= 0.106
PaCO2 (mmHg) 51.14 ± 25.18 68.56 ± 11.97
tp= 0.120
pH 7.31 ± 0.08 7.32 ± 0.06 tp= 0.633
Bicarbonate (mmol/L) 23.36 ± 7.90 33.87 ± 5.26 tp= 0.012*
tp: p value for Student t-test.
* Statistically significant at p 6 0.05.
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Figure 5 Bicarbonate level in group IIa and group IIb.
Figure 6 Correlation between apnea/hypopnea index (AHI) and neck circumference.
Sleep related breathing disorders 95fulfilled the criteria of obesity hypoventilation syndrome
(OHS): awake PaCO2P 45 mmHg, BMIP 30 kg/m
2 and
absence of other causes of alveolar hypoventilation due to
intrinsic lung pathology [11]. Seven of those 17 patients
(9.7% of all admission) had BMIP 40 kg/m2 and concomi-
tant metabolic syndrome. This is a combination newly called
malignant obesity hypoventilation syndrome (MOHS) [12].
Five of them had elevated liver enzymes maybe due todeveloping of nonalcoholic steatohepatitis. The remaining 15
(46.9%) out of 32 patients in group IIb, who represented
38.4% of patients with SRBDs, showed SHV attributed to
other cause than OHS: COPD in 14 patients and congenital
central hypoventilation in one patient.
Finally, we studied the correlations of the AHI with all the
other parameters of the study. It showed a significant direct
correlation with neck circumference (r= 0.333, p= 0.014)
Figure 7 Correlation between apnea/hypopnea index (AHI) and systolic blood pressure.
96 M.I. Mahmoud et al.(Fig. 6), systolic blood pressure (r= 0.329, p= 0.041) (Fig. 7),
snoring index (r= 0.488, p= 0.002) and T85% (r= 0.333,
p= 0.038). Moreover, it was found to be significantly
higher in patients with diabetes mellitus than in those
without (Z= 2.325, p= 0.048). It had a significant inverse
correlation with PaO2 (r= 0.395, p= 0.013), minimal satu-
ration (r= 0.477, p= 0.002) as well as average saturation
(r= 338, p= 0.036). Lastly, it did not show any significant
correlation with age (r= 0.044, p= 0.791), BMI (r= 0.239,
p= 0.074) nor clinical apnea score (r= 0.233, p= 0.153).Discussion
In our study, 71% of patients admitted to ICU had a high clin-
ical probability of SRBDs; and actually all of them who under-
went sleep study were proven to have at least one sleep
disorder, as all of them suffered from OSAHS. In concor-
dance, Goring et al. [13] who evaluated 94 patients found that
77% of patients suffered from SRBDs proved by polysomno-
gram and the vast majority of those (95%) had OSAHS. Sim-
ilarly, Adly et al. [14] in his study of the prevalence of SRBDs
in patients with acute coronary syndrome admitted to ICU,
found that 70% of his patients suffered from SRBDs including
OSAHS (50%) and central sleep apnea – Cheyne–Stokes
breathing (20%). Richards et al. [15] reported a lower preva-
lence of SRBDs in coronary care unit being 47% including
both obstructive and central etiologies.
We found that 82% of patients with SRBDs suffered also
from SHVS; and 53% of those fulfilled criteria of OHS. Now-
bar et al. [16] prospectively evaluated obese patients with
BMIP 35 admitted to hospital in an attempt to determine
the percentage of patients meeting the criteria for OHS versus
simple obesity. They reported 6% to be obese patients and
31% of those suffered from OHS. We found 7 patients of those
with OHS, who constituted 9.7% of all admission, suffering
from MOHS and 71.4% of those, were females. Likewise,
Marik et al. [12] reported a prevalence of MOHS in all patients
admitted over an eight month period, of 8% of all admissionsand 77% of them were females. Forty-one percent of our
patients with OSAHS had SHVS caused by COPD: overlap
syndrome. Those represented 21% of all admissions. Chaouat
et al. [17] found the prevalence of sleep apnea in COPD
patients to be 10–15%. Zammaron et al. [18] stated that over-
lap syndrome population tends to be older than the simple
OSA population, with more frequent hypoxemia and hyper-
capnia, higher mean pulmonary artery pressures, but similar
BMI.
The age of our patients with SRBDs was significantly
higher than that of patients without SRBDs; a finding in agree-
ment with the fact that SRBDs increase with age. The BMI
and neck circumference of our patients with SRBDs were also
significantly higher than that without SRBDs. Mortimore et al.
[19] showed that neck circumference is the anthropometric
measurement most closely associated with OSA, even in those
with a normal BMI. We also found a significant positive cor-
relation between AHI and neck circumference but there was
no correlation between AHI and BMI. Caffo et al. [20] found
neck circumference to be the most important predictor of
OSAHS severity and to a lesser extent BMI, waist circumfer-
ence, age and frequency of snoring. When we compared the
anthropometric data of patients with SHVS and those without,
there were no significant differences between the two groups.
Shimura et al. [21] reported that leptin level was the only vari-
able predictive of hypoventilation in Japanese men with OSA;
whereas BMI, measures of OSA severity and visceral or subcu-
taneous fat measurements were not predictive of hypercapnia.
Systemic comorbidities are known to be higher in patients
with SRBDs. In our study, the incidence of DM was much
higher, almost double, in patients with SRBDs than in patients
without SRBDs. The Wisconsin Sleep Cohort study [22]
reported a 2-fold increase in risk of DM in 51387 subjects with
OSA (defined by AHIP 15) after adjustment for confounders.
Tamura et al. [23] reported a prevalence of DM as high as 30%
in 129 Japanese middle-aged adults with OSAHS. We also
found that the AHI was significantly higher in diabetic patients
than in non-diabetic ones and the post-prandial blood sugar
was significantly higher in patients with SRBDs. Aurora
Sleep related breathing disorders 97et al. [24] found the AHI and average oxygen saturation during
sleep to be associated with elevated fasting and post-prandial
glucose levels. Our patients with SRBDs had a significantly
higher incidence of systemic hypertension compared to
patients without SRBDs. In accordance, Silverberg et al. [25]
found that about 50–60% of patients with SRBDs had
systemic hypertension in comparison to only about 20% of
general population; showing about 3 times more risk. We also
found that AHI was positively correlated with systolic blood
pressure value. Nieto et al. [26] previously reported this
finding. Pulmonary hypertension was encountered in about a
third of all of our patients, but it was not associated with the
presence of SRBDs. Such lack of association was reported
before [13]. We attributed the high prevalence of pulmonary
hypertension to the high prevalence of COPD in both groups
and OHS in patients with SRBDs. Indeed, COPD was by far
the commonest concomitant intrinsic lung disease in our
patients being significantly higher in patients without SRBDs.
COPD, being a disease associated with systemic inflammation
and many comorbidities, could alter the usual milieu of comor-
bidities allied with SRBDs.
Our laboratory investigations showed that serum uric acid
was significantly higher in patients with SRBDs than in those
without SRBDs. Garcia et al. [27] found 36% of patients with
SRBDs had serum uric acid above established normal values.
Also Marinchev et al. [28] reported that patients with gout and
hyperuricemia have more severe OSAHS than subjects with
osteoarthritis and OSAHS. The serum cholesterol and triglyc-
erides were significantly higher in our patients with SRBDs.
Togeiro et al. [29] studied a total of 1042 volunteers polysomnog-
raphy, found subjectswithmoderate to severeOSA tohave hither
triglycerides levels than did the mild and non-OSA subjects. In
fact, it was reported that nocturnal intermittent hypoxemia is
independently associated with metabolic dyslipidemia [30].
Type II respiratory failure was by far the commonest cause
of ICU admission of all of our patients; and it was a signifi-
cantly higher cause in patients with SRBDs. Confalonieri
et al. [31] who conducted a cohort study in 26 respiratory
ICU, found that 581 patients (68%) had type II respiratory fail-
ure. BaHammam et al. [32] who studied respiratory failure in
obese patients with SRBDs found that the reason for ICU
admission for all subjects was type II respiratory failure. How-
ever, El-Solh et al. [33] found that most morbid obese patients
including those with SRBDs were hospitalized most frequently
because of type I respiratory failure. Noninvasive ventilation
(NIV) precisely BiPAP was the cardinal mode of ventilation
used in our patients with SRBDs. Bi-level NIV is the first line
of management of acute hypercapnic respiratory failure in
patients with OHS and OSAS. Carrillo et al. [34] studied 716
patients with type II respiratory failure (173 with OHS and
543 with COPD) and treated with a similar protocol of NIV.
They concluded that patients with OHS were treated with sim-
ilar efficacy but better outcomes than patients with COPD. We
used invasive mechanical ventilation initially in patients with
absolute contraindication to NIV or patients who failed to
improve by it. Confalonieri et al. [31] in their study, found
56% of ICU patients needed NIV as first line of management
where 21% of them needed invasive mechanical ventilation.
Our patients with SRBDs had significantly less frequent
repeated admission than those without SRBDs. This could be
due to the fact that patients without SRBDs had significantly
higher existence of an intrinsic pulmonary disease mostly irre-versible leading to difficult and worse prognosis. In addition,
SRBDs are treatable disorders once properly diagnosed.
The daytime arterial oxygen tension of our patients showed
a significant inverse correlation with AHI; a finding which
could be explained by the fact that most of our patients had sev-
ere OSAHS and hypoventilation syndrome. As we compared
the arterial blood gases parameters of patients with SRBDs
associated with SHVS and those without SHVS, we found only
serum bicarbonate level to be significantly higher in patients
with SHVS. Macavei et al. [35] confirmed a high prevalence
of OHS in obese patients with OSAHS and reported that a high
bicarbonate level (>27 mmol/L) to be one of the most sensitive
and specific predictors for the diagnosis of OHS.
Regarding sleep stages, light sleep stage time was encroach-
ing on deep sleep stage time and REM sleep stage with reduced
total sleep time. Such findings were comparable to those
reported by Goring et al. [13] Sleep disruption has been recog-
nized as a complication of acute illness. It is characterized by
reduced nocturnal sleep efficiency and altered sleep architec-
ture with increased wakefulness and stage 1 Non-REM sleep,
together with reduced deep sleep and REM sleep [4]. Freed-
man et al. [36] studied 22 patients admitted to medical ICU
(20 of whom were mechanically ventilated) to determine the
effect of environmental noise on sleep disruption. Studied
patients were found to be qualitatively and not necessarily
quantitatively sleep deprived and environmental noise was
not responsible for the majority of sleep fragmentation.
Limitations of the study
The sleep study should have been performed in every patient
admitted to ICU and not only the high clinically predicted,
as long as it is feasible to test the specificity of the clinical
apnea score in such critically ill patients. Also the diagnosis
of COPD in most patients was clinically and radiologically
based and not by spirometry.
Conclusion
In ICU patients, SRBDs are common coexistent findings and
every physician should systematically search for them. Type
II respiratory failure is the main cause of ICU admission in
patients with SRBDs. Quality of sleep in ICU is very dis-
turbed. Most ICU patients with SRBDs have concomitant
SHVS mostly due to OHS. Important comorbidities coexist
in patients with SRBDs; both influence each other and should
be identified and managed properly for the wellbeing of the
patient. BiPAP therapy is the cardinal mode of ventilation
used in patients with respiratory failure and SRBDs.
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